NEW YORK, NY--(Marketwired - Jan 23, 2015) - Kadmon Corporation, LLC, today announced that Gregory S. Moss, Vice President, Office of General Counsel at Kadmon, will present at CBI's 12th Annual Pharmaceutical Compliance Congress, taking place January 27�28 in Washington, D.C. Mr. Moss will moderate a panel on the fundamentals of healthcare compliance, titled "Basics in Healthcare Compliance and Policy Applications." Mr. Moss will also participate in a panel discussion on compliance at small pharmaceutical companies, titled "Small to Mid-Size Businesses: Utilization and Allocation of Resources."
At Kadmon, Mr. Moss is responsible for the development and implementation of the company's compliance program and for a broad range of legal and compliance issues across its corporate and pharmaceutical divisions. Mr. Moss serves as Deputy Chairman of Kadmon's Internal Compliance Committee and is a member of the company's promotional review committees.
CBI's Pharmaceutical Compliance Congress is the premier forum for the life science industry's legal, compliance and regulatory executives and government agency leaders to share best practices for corporate compliance programs. For more information, visit www.cbinet.com/PCC.
About Kadmon Corporation
Kadmon Corporation, LLC, is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in oncology, autoimmune and fibrotic diseases, monogenic diseases and metabolic disease. For more information, visit www.kadmon.com.
This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
